Question 1

Has any study given Semax and Selank to the same people?

Accepted Answer

One has, and it looked at brain scans rather than at symptoms. A 2020 Russian experiment ran resting-state functional MRI in 52 healthy participants, scanning each person before, after 5 and 20 min of the injection of either Semax, or Selank, or placebo. That is the only place in these sources where both compounds and a dummy injection sit in one protocol. The authors write that post hoc analysis allowed us to define both general and specific effects of Selank and Semax on FC between the right amygdala and the right temporal cortex for the first time, where FC means functional connectivity, a measure of how closely two regions rise and fall together. Take that as a starting point and not as a verdict. A difference in connectivity twenty minutes after an injection is not a difference in attention, mood or anxiety, and no study among the sources behind this page has scored those outcomes in the same people given each compound. The animal side of the same question is set out at the Selank comparison page.

Question 2

Semax or Selank for brain fog and focus?

Accepted Answer

Brain fog is not an endpoint anyone in this literature set out to move, so the honest comparison is between what each compound was measured on. For Semax that is injury and deficit rather than ordinary tiredness. A 2018 Russian imaging study scanned two groups of healthy volunteers and reported that a greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls, that network being the set of regions which idles when attention is not pointed outward. The paper carries no cognitive test beside the scan. The animal work points the same way. Across six nootropic compounds given to mice, changes in the BDNF level were only observed in the hippocamp of LE mice, the low-efficacy mice that explored a maze poorly, and the authors conclude the effect is achieved only under conditions of cognitive deficiency. BDNF is a growth factor that keeps nerve cells alive. So the pattern here is repair rather than enhancement. A compound that moves a marker in an impaired rodent has not been shown to move anything in a person whose focus is merely below their own standard, and those are different questions.

Question 3

Is Semax the same as semaglutide?

Accepted Answer

No. The names share three letters and the molecules share nothing, and one review files them under different headings. Semax came out of stress-hormone research. A 2024 stroke paper states the starting point plainly: adrenocorticotropic hormone (ACTH) serves as the basis for the creation of synthetic peptides as neuroprotective agents for stroke therapy. A 2026 review of peptides in ageing sorted nine compounds by what they are aimed at, and Semax appears on the line for neuroprotection (Semax). Weight and blood sugar sit on a different line of that same list, under metabolic restoration (tirzepatide). Semax is not on it. What the research on semaglutide measures is set out at the Semaglutide overview, and among the sources behind this page no research attributes a change in body weight to Semax. So the confusion is a naming accident rather than a pharmacological one, and nothing follows from the shared prefix.

Question 4

What does the acetyl group change in N-Acetyl Semax Amidate?

Accepted Answer

The marketed name describes chemical caps on the ends of the chain, and one laboratory paper has measured what the front cap does. A 2016 chemistry study reports that n-terminal amino group acetylation (Ac-Semax) modulates the chemical and biological properties of parental peptide, which says the capped molecule is chemically a different thing and not a stronger version of the same one. The difference it measured was in metal handling: the two forms bind copper through different arrangements, while on zinc both were able to form Zn(II) complex species with comparable strength. Where the capped form met a living cell it did worse. The same paper found that semax acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line, which is a human nerve-cell line kept alive in a dish. That is the whole published comparison between the two forms, and it runs the opposite way to the sales pitch. A molecule that lasts longer in glassware is not the same claim as a molecule that does more in a brain, and the second has not been tested in the work covered here.

Question 5

Is Adamax a different compound from Semax?

Accepted Answer

Adamax is a product name rather than a studied molecule, and no source we could find in this literature names it or matches it to a sequence. Two modified Semax molecules do appear in the published work. One is the acetylated form above. The other is unnamed: a 2025 experiment assessed the effect of the known neuroprotective peptide Semax and its derivative on the behavioral characteristics and development of amyloidosis in transgenic APPswe/PS1dE9/Blg mice, a strain bred to build up the plaques seen in Alzheimer's disease. In that model both Semax and its derivative improved cognitive functions in mice, and the paper never gives the derivative a trade name. So a reader comparing Adamax against Semax is comparing a label against a molecule rather than one molecule against another, which means a claim of that shape cannot be checked against a paper at all.

Question 6

How does Semax compare with its own ACTH fragments?

Accepted Answer

This is where the real head-to-head work sits, and all of it is in rodents. Two gene-sequencing experiments ran Semax against ACTH(6-9)PGP, a shorter relative built from a neighbouring piece of the same hormone. In the stroke model the authors analyzed the penumbra-associated frontal cortex of rats and actions under the same peptides at 24 h after tMCAO using RNA-Seq, tMCAO meaning a temporary blockage of a brain artery. Their conclusion was close to a tie, since the effect of ACTH(6-9)PGP was more similar to Semax than different from it a day after tMCAO. In undamaged rats the two separated a little. The same group identified 258 and 228 DEGs, respectively, where a DEG is a gene switched measurably up or down against saline, and reported that both peptides predominantly caused decrease in expression of the genes associated with the immune system. A third study widened the family. It analyzed the ability of some biologically active synthetic corticotropins (ACTH(4-7)PGP, ACTH(6-9)PGP, ACTH(7-10)PGP), and glyproline PGPL to affect the GABA-receptor system of rat brain, and found that the studied peptides individually affected the binding of [3 H]GABA in their own way. These are gene-expression and receptor-binding comparisons in rodents. They say which molecules behave alike inside a rat cortex; they say nothing about which one a person would notice.

Question 7

Is Pinealon in the same category as Semax?

Accepted Answer

Not in the one review that sorts this field into groups. A 2026 orthopaedic review arranged the compounds it covered by the systems they are thought to act on, and pinealon lands elsewhere: recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators. Semax appears in the next clause of the same sentence, grouped with the neuroactive peptides rather than with the circadian ones. A 2026 ageing review draws the same boundary from a different direction, listing the compounds it examined by aim and filing Semax under neuroprotection (Semax). Neither review reports an experiment in which pinealon and Semax were given to the same animals. So the category question has an answer and the comparison question has none. Grouping two compounds by mechanism is a statement about theory rather than about outcome, and the orthopaedic review is blunt about what sits behind the theory: although preclinical studies are promising, there is a current lack of clinical trials.

Question 8

Can I take Semax and Selank together?

Accepted Answer

The published record does not reach that question. The three-arm scanning study gave each compound on its own against a dummy injection rather than in combination, and a combination arm is what would be needed to see a combined effect. A 2026 ageing review names the hole directly, listing among its open items that significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. That phrase is written as a gap for the whole class of compounds the review covers rather than for this pair alone. One 2005 paper does group the two together, by chemistry. It argues that the ability of glyprolines to pass gastro-enteric tract barriers opens ways to per-oral administration of this new group of drugs such as semax, selank and their fragments, and that the activity of such peptides as semax and selank may have value across a range of conditions. That is a shared argument about stability rather than a shared effect, and two molecules surviving the same enzymes does not predict what they do in company. What happens when Selank is put together with something else has been measured, and that work is set out at the Selank comparison page.

Question 9

What has Semax been combined with in published work?

Accepted Answer

With ordinary medical care, every time. Every human study of Semax in these sources added it to something else rather than testing it alone. The optic nerve work from 2000 says so outright. It was given in parallel with basic neurotrophic and antiinflammatory therapy, and the paper's claim is that addition of semax to therapeutic complex in patients with diseases of the optic nerve had a favorable impact on the intensity and rate of recovery and improved the visual functions. The 2001 glaucoma report is built the same way, as a complex of neuroprotective therapy, including a new Russian neuropeptide semax. The stroke study followed the pattern. All patients were divided into early (89±9 days) and late (214±22 days) rehabilitation groups, each subdivided into semax+ and semax- subgroups, so the peptide sat on top of a physiotherapy programme in every arm. That matters to anyone planning a stack. The effect attributed to Semax in people is the extra on top of something already working, which is a different claim from the one a stack implies.

Question 10

What is sold as a Semax and Selank nasal spray?

Accepted Answer

The nose is the route Semax has been studied in most, and every published description is of one compound at a time rather than of a mixture. Both brain-imaging studies used it. The 2018 work scanned its volunteers 5 and 20 min after intranasal 1% Semax (14 subjects) or placebo (10 subjects), a concentration rather than a weight. The 2000 optic nerve study split its patients by delivery method: in group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control. Two nasal methods plus an untreated group is a route experiment rather than a compound experiment, and it says the people doing the work treated delivery as a live variable. No study among the sources behind this page has put both compounds into one spray or measured what a mixture delivers. The dose arithmetic for the Semax side of it is set out at the Semax dosage page.

Question 11

What is documented about side effects of Semax and Selank?

Accepted Answer

Neither literature was designed to find harm, and the two record it in different ways. For Semax, adverse events are mostly absent from the papers rather than reported as zero. The 110-patient stroke study lists what it measured: plasma BDNF levels, motor performance on the British Medical Research Council scale and Barthel index were assessed in all groups. Side effects are not on that list, so the silence is a gap in the reporting rather than a finding about the compound. A 2026 ageing review that searched FDA and WADA records puts the whole class in the same place, concluding that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. One 2024 rat paper argues from the other side that it is necessary to study influence of the peptide on the brain cells under normal physiological conditions, including understanding the risks of their use. The Selank side of this comparison has a differently shaped record, set out at the Selank comparison page. A literature that never collected adverse events and one that collected them and found none produce the same empty column, and an empty column is not the same as a clean one.

Question 12

How strong is the Semax evidence next to Selank's?

Accepted Answer

Count the designs, not the papers. The paper count flatters both of them. The Semax human record here is one stroke study of one hundred and ten patients after IS, two small eye studies from 2000 and 2001, and two brain scans with a placebo arm in healthy people. The stroke study split patients by when their therapy began, then by whether they got the peptide. That is a split by timing rather than a draw from a hat, yet the paper still reports that early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance. The two brain scans are the tightest work on the Semax side, and what they measure is a picture. The eye studies are small and never say how patients were put into groups. So the question most readers arrive with, which one works better, cannot be answered from these sources. No study among the sources behind this page scores the two on one outcome in one group of people. The study that gave both measured connectivity, and connectivity is not a symptom.

Question 13

What happened when Semax was run against Melanotan II?

Accepted Answer

One rat study put Semax beside a different relative of the same hormone, and the two came out level on almost everything. The design was plain enough. Stressed and control male adult Sprague-Dawley rats received daily intraperitoneal injections of saline or a low dose (60 nmol/kg of body weight (BW)) of Semax or MTII, where intraperitoneal means into the belly and MTII is the tanning peptide Melanotan II. On the stress measures the two moved together. The paper reports that chronic treatment with Semax and MTII reversed or substantially attenuated CUS-induced anhedonia, BW gain suppression, adrenal hypertrophy and a decrease in the hippocampal levels of BDNF. CUS is the long run of stress the rats were put through, and anhedonia here means a lost taste for sugar water. One measure went the other way for both of them. In the forced swim test, no effects of the CUS procedure or peptides on the duration of rat immobility were detected. That is the test most used to claim an antidepressant effect in rodents, and neither compound moved it. Two compounds shifting the same markers in the same rats is the cleanest head to head in the Semax work, and it is still a rat under stress. It says the molecules act alike in that model, and it says nothing at all about either one in a person who is not stressed.

Semax comparisons and stacks